ACC 22: APOLLO FIH Study to Investigate siRNA in Raised Lipoprotein(a) | Dr Steven E Nissen

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short summary interview, Dr Steven E Nissen (Cleveland Clinic, Cleveland, OH, US) talks about detailed results from the APOLLO study. This placebo-controlled double-blind dose-ranging trial investigated the safety and tolerability of SLN360 (Silence Therapeutics plc) in patients with elevated Lipoprotein(a) (NCT01960348).

Discussion Points:
-Trial Rationale
-Mechanism of Action
-Study Design and Inclusion Criteria
-Key Results
-Next Steps
-Take-home Messages

Filmed on-site at ACC.22, Washington.
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.